This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: New Insight Into Retail Investors

Lots of people mentioned stocks that just don't get talked about, yet which have been remarkable in their consistency: Express Scripts ESRX, AmerisourceBergen (ABC) and McKesson (MCK), three health care-cost-containment plays that many people are picking as big winners off of the Affordable Care Act. Some people asked that I do segments on these for Mad Money because they want more knowledge.

Lots of people wanted to know if Yahoo! (YHOO) could keep going higher, and how much of the gain has been from Alibaba, and how much has been from actions taken by CEO Marisa Meyer. Instead of answering, I asked what they thought -- and they all, to a person, said it was because of the burgeoning Alibaba stake and that the rally could therefore continue.

Many wanted to know if Google (GOOG) could go higher and whether Apple's (AAPL) better or worse than Google. You don't have much time to answer the question before the line starts surging, but I plaintively say these names are different: Apple is a value play, and Google is a momentum story, albeit one of the cheapest of that ilk out there. No one complained or tried to change my mind.

Finally, many own Celgene (CELG) or Gilead (GILD), two stocks that I have been behind for many years, which some describe as "core holdings." Again, so much for retail investors not knowing how the professional game is played: Both of these stocks have been winners without super-high valuations. Many, of course, said they wanted to find the next Intercept Pharma (ICPT), the stock that rallied 400 points last week. Sorry, I don't have one, I answered.

Must Read: Disastrous Unemployment Data; A Lurking China: Jim Cramer's Best Blogs

Sure, there were plenty who asked if Rite Aid (RAD) and Sprint (S) were "still good." I responded that Rite Aid could just keep powering higher as part of a strong trio that includes CVS (CVS) and Walgreen (WAG). Sprint, I think, is way overbought for the short term. But, with the help of Softbank, I think the combination of bountiful spectrum and deep pockets will mean there could be a longer-term triumph.

Sure, the group might be self-selective, as I am sure the turnout will be Wednesday night at the 92nd Street Y in Manhattan, where Stephanie Link and I will spar after that night's Mad Money. There were, indeed, a lot of "booyahs" to start each interchange. But I think the signings, touching about 1,000 people, forged a bit of a bridge between the empirical and the anecdotal: The investors want solid stocks that can go up for years -- not days or, alas, minutes, as so many pros seem to crave.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long BAC, GOOG and AAPL.

Editor's Note: This article was originally published at 6 a.m. EST on Real Money on Jan. 13.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs